Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release
(XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine
versus Lithium in combination with an selective serotonin reuptake inhibitor or Venlafaxine
versus Quetiapine extended release monotherapy in subjects with treatment resistant
depression as assessed by the changes from randomisation to week 6 in the Montgomery-Åsberg
Depression Rating Scale (MADRS) total score. As an independent objective, the primary
objective will also be evaluated in two subgroups of patients: (1) patients who were
resistant to two previous antidepressant therapies and (2) in the subgroup of patients with
one previous failure.